(NASDAQ: SRZN) Surrozen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.
Surrozen's earnings in 2025 is -$104,844,000.On average, 4 Wall Street analysts forecast SRZN's earnings for 2025 to be -$103,340,480, with the lowest SRZN earnings forecast at -$99,287,912, and the highest SRZN earnings forecast at -$106,379,906. On average, 4 Wall Street analysts forecast SRZN's earnings for 2026 to be -$36,982,253, with the lowest SRZN earnings forecast at -$40,235,964, and the highest SRZN earnings forecast at -$33,029,971.
In 2027, SRZN is forecast to generate -$33,397,685 in earnings, with the lowest earnings forecast at -$41,243,964 and the highest earnings forecast at -$24,569,978.